Iron Restriction to Clinical Isolates of Candida albicans by the Novel Chelator DIBI Inhibits Growth and Increases Sensitivity to Azoles In Vitro and In Vivo in a Murine Model of Experimental Vaginitis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Candida albicans is an important opportunistic pathogen causing various human infections that are often treated with azole antifungals. The U.S. CDC now regards developing candidal antifungal resistance as a threat, creating a need for new and more effective antifungal treatments. Iron is an essential nutrient for all living cells, and there is growing evidence that interference with iron homeostasis of C. albicans can improve its response to antifungals. This study was aimed at establishing whether withholding iron by currently used medical iron chelators and the novel chelator DIBI could restrict growth and also enhance the activity of azoles against clinical isolates of C. albicans. DIBI, but not deferoxamine or deferiprone, inhibited the growth of C. albicans at relatively low concentrations in vitro, and this inhibition was reversed by iron addition. DIBI in combination with various azoles demonstrated stronger growth inhibition than the azoles alone and greatly prolonged the inhibition of cell multiplication. In addition, the administration of DIBI along with fluconazole (FLC) to mice inoculated with an FLC-sensitive isolate in a model of experimental C. albicans vaginitis showed a markedly improved clearance of infection. These results suggest that iron chelation by DIBI has the potential to enhance azole efficacy for the treatment of candidiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Modulation of iron levels alters C. albicans dissemination, infection severity, membrane ergosterol levels, and host immune response (largely mediated by iron-induced changes in the levels of immunogenic glucans in the cell wall) (22–25).”
From Candida albicans enhances iron uptake to maintain fluconazole resistance (2025) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“are commonly associated with health care-associated infections in the United States as well as worldwide (1).”
BackgroundSynergy, antagonism, and what the chequerboard puts between them
Odds, F. C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg301 · Cited by 2,481
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
An integrated model of the recognition of Candida albicans by the innate immune system
Netea, M. G., Brown, G. D., Kullberg, B. J., & Gow, N. A. R. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1815 · Cited by 946 · cited 1×
“It is becoming increasingly clear that the innate immune response is an important host defense against Candida infection (13), with iron availability and sequestration being important components of susceptibility and immunity (14–16).”
BackgroundThe Battle for Iron between Bacterial Pathogens and Their Vertebrate Hosts
Skaar, E. P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000949 · Cited by 796
Iron availability and infection
Weinberg, E. D. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.07.002 · Cited by 516
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389 · cited 1×
“Additionally, FLC administered orally is highly bioavailable rapidly 204 entering the systemic circulation for delivery to tissues including into vaginal secretions but with 205 >60% of the FLC load being eliminated non-metabolized and intact via urinary excretion (41).”
BackgroundEpidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376 · cited 1×
“predisposing host factors are implicated in infection (12).”
Background
Research works printed but not linked: 2
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard—3rd ed CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
- Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA. [Google Scholar]
Cited by
Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 164
Sheng, M. M., Jia, H. K., Zhang, G. Y., Zeng, L. N., Zhang, T. T., Long, Y. H., Lan, J. Q., Hu, Z. Q., Zeng, Z., Wang, B., et al. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1910.10066 · Cited by 90
Jin, X., Zhang, M., Lu, J., Duan, X., Chen, J., Liu, Y., Chang, W., & Lou, H. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.016 · Cited by 75
Iron‐MOFs for Biomedical Applications
Yu, Z., Lepoitevin, M., & Serre, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402630 · Cited by 73
Tripathi, A., Liverani, E., Tsygankov, A. Y., & Puri, S. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013413 · Cited by 56
Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox
Kane, A., & Carter, D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040482 · Cited by 58
Nocera, F. P., & Martino, L. D. (2024) · Veterinary Research Communications · doi:10.1007/s11259-024-10508-8 · Cited by 58
“…active against other Gram-positive as well as Gram-negative bacteria ( S. aureus and Acinetobacter baumannii ) (Ang et al. 2018 ; Parquet et al. 2018, 2019) and fungi ( Candida albicans ) (Ang et al. 2018; Savage et al. 2018), thereby proving to be a useful drug for management of mixed infections.”
BackgroundModulation of Iron Metabolism in Response to Infection: Twists for All Tastes
Gomes, A. C., Moreira, A. C., Mesquita, G., & Gomes, M. S. (2018) · Pharmaceuticals · doi:10.3390/ph11030084 · Cited by 55
Parquet, M. D. C., Savage, K. A., Allan, D. S., Davidson, R., & Holbein, B. E. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01811 · Cited by 54
Self-citationPuri, S., Kumar, R., Rojas, I. G., Salvatori, O., & Edgerton, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02152-18 · Cited by 48
“when administered along with fluconazole in a mouse model (23).”
BackgroundHost-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis
MacAlpine, J., & Lionakis, M. S. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.08.018 · Cited by 49
DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity
Ang, M. T. C., Gumbau‐Brisa, R., Allan, D. S., McDonald, R., Ferguson, M. J., Holbein, B. E., & Bierenstiel, M. (2018) · MedChemComm · doi:10.1039/c8md00192h · Cited by 42
Self-citationSala, A., Ardizzoni, A., Spaggiari, L., Vaidya, N., van der Schaaf, J., Rizzato, C., Cermelli, C., Mogavero, S., Krüger, T., Himmel, M., et al. (2023) · mBio · doi:10.1128/mbio.00107-23 · Cited by 37
“albicans virulence in both oral and vaginal murine disease models, although this might be attributable to a direct antifungal effect as well (68, 69).”
BackgroundParquet, M. D. C., Savage, K. A., Allan, D. S., Ang, M. T. C., Chen, W., Logan, S. M., & Holbein, B. E. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00855-19 · Cited by 30
“DIBI also displays broad-spectrum antimicrobial activities (14–17) and has been shown to enhance the activities of conventional antibacterial and antifungal antibiotics when applied with these at relatively low concentrations (16, 17).”
BackgroundSelf-citationHolbein, B. E., Ang, M. T. C., Allan, D. S., Chen, W., & Lehmann, C. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01242-7 · Cited by 29
Self-citationZinc and Iron Homeostasis: Target-Based Drug Screening as New Route for Antifungal Drug Development
Simm, C., & May, R. C. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00181 · Cited by 26
“Several studies on adjunct treatment of metal chelators, such as EDTA, dibromoquinoline, or DIBI, and azoles showed markedly reduced susceptibility of fungi toward these combinations in comparison with antifungal monotherapy (Casalinuovo et al., 2017; Mohammad et al., 2018; Savage et al., 2018).”
ResultDuval, C., Macabiou, C., Garcia, C., Lesuisse, E., Camadro, J., & Auchère, F. (2019) · MicrobiologyOpen · doi:10.1002/mbo3.970 · Cited by 29
“Moreover, it has recently been shown that limiting iron levels with the novel chelator DIBI (a hydroxypyridinone-class chelator) inhibits C. albicans growth and increases susceptibility to azoles in a murine model of vaginitis (Savage et al., 2018).”
BackgroundKirienko, N. V., Rahme, L. G., & Cho, Y. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00343 · Cited by 26
“DIBI also inhibits the growth of Candida albicans and increases its sensitivity to azole drugs in vitro and in vivo (Savage et al., 2018).”
BackgroundCandida albicans reprioritizes metal handling during fluconazole stress
Hunsaker, E. W., & Franz, K. J. (2019) · Metallomics · doi:10.1039/c9mt00228f · Cited by 22
Comparison of Treatment Effects of Different Iron Chelators in Experimental Models of Sepsis
Lehmann, C., Aali, M., Zhou, J., & Holbein, B. E. (2021) · Life · doi:10.3390/life11010057 · Cited by 22
“DIBI also demonstrated synergistic effects with fluconazole to lower vaginal fungal burden, but alone, it did not reduce fungal burden [36].”
BackgroundSelf-citationThe intricate link between iron, mitochondria and azoles in Candida species
Genechten, W. V., Vergauwen, R., & Dijck, P. V. (2023) · FEBS Journal · doi:10.1111/febs.16977 · Cited by 25
“Additionally, iron limitation, mimicked by chelation of iron by bathophenanthrolinedisulfonic acid, desfer-rioxamine, ferrozine or DIBI, increased the susceptibility of C. albicans to fluconazole [25,26].”
Şumlu, E., Aydın, M., Korucu, E. N., Alyar, S., & Nsangou, A. M. (2024) · Antibiotics · doi:10.3390/antibiotics13040310 · Cited by 21
“Iron limitation or iron chelators have increased the in vitro activity of various antifungal Iron limitation or iron chelators have increased the in vitro activity of various antifungal agents in C. albicans [31]. agents in C. albicans [31].”
BackgroundPseudomonas Synergizes with Fluconazole against Candida during Treatment of Polymicrobial Infection
Hattab, S., Dagher, A.-M., & Wheeler, R. T. (2022) · Infection and Immunity · doi:10.1128/iai.00626-21 · Cited by 22
Fokam, D., Dickson, K., Kamali, K., Holbein, B. E., Colp, P., Stueck, A., Zhou, J., & Lehmann, C. (2020) · Antibiotics · doi:10.3390/antibiotics9060283 · Cited by 17
Self-citationAn, L., Tan, J., Wang, Y., Liu, S., Li, Y., & Yang, L. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00725-22 · Cited by 18
Allan, D. S., Parquet, M. D. C., Savage, K. A., & Holbein, B. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02353-19 · Cited by 14
Self-citationAbbina, S., Gill, A., Mathew, S., Abbasi, U., & Kizhakkedathu, J. N. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c06501 · Cited by 15
Iron metabolismin conditions of infection. Review
Orlov, Y. P., Говорова, Н. В., Лукач, В. Н., Baytugaeva, G. A., Klementyev, A. V., & Николаевич, К. Е. (2020) · Annals of critical care · doi:10.21320/1818-474x-2020-1-90-99 · Cited by 32
Iron should be restricted in acute infection
Lehmann, C. D. (2019) · Frontiers in bioscience · doi:10.2741/4827 · Cited by 12
Gumbau‐Brisa, R., Ang, M. T. C., Holbein, B. E., & Bierenstiel, M. (2020) · BioMetals · doi:10.1007/s10534-020-00253-1 · Cited by 12
Self-citationNocera, F. P., Iovane, G., Martino, L. D., & Holbein, B. E. (2022) · Pathogens · doi:10.3390/pathogens11060656 · Cited by 11
“Given other studies have shown DIBI to have activity for both AR Gram-negative bacteria [15] and AR yeast [16], DIBI appears to have broad anti-microbial and anti-infective activities, which are independent of the antimicrobial resistance profile of the particular bacterial pathogen.”
BackgroundSelf-citationMechanisms and regulation of iron uptake and the role of iron in pathogenesis of Candida albicans
Zheng, D., Zhang, X., Ding, J., Yue, D., Yang, F., & Li, Y. (2025) · Critical reviews in microbiology · doi:10.1080/1040841x.2025.2510256 · Cited by 10
“…thiosemicarbazone derivatives and Dibi, have demonstrated significant antifungal activity against C. albicans in both in vitro and in vivo settings (Savage et al. 2018; Duan et al. 2022). therefore, therapeutic strategies targeting iron homeostasis—including iron uptake inhibitors, iron chelation…”
Chai, X., Jiang, Y., Lu, H. J., & Huang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574990 · Cited by 9
Gal, Y., Marcus, H., Mamroud, E., & Aloni-Grinstein, R. (2023) · Microorganisms · doi:10.3390/microorganisms11071701 · Cited by 9
Candida albicans enhances iron uptake to maintain fluconazole resistance
Sharma, R., Nahar, A., & Puri, S. (2025) · Infection and Immunity · doi:10.1128/iai.00002-25 · Cited by 8
“Susceptibility of C. albicans to fluconazole increased in the presence of various iron chelators, such as bathophenanthrolinedisulfonic acid, deferoxamine, ferrozine, or DIBI (23, 26, 28), while desferrioxamine was also shown to synergistically enhance the susceptibility of C. glabrata to fluconazole (29).”
Bortolami, M., Pandolfi, F., Messore, A., Rocco, D., Feroci, M., Santo, R. D., Vita, D. D., Costi, R., Cascarino, P., Simonetti, G., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128087 · Cited by 11
Itoh, K., Tsutani, H., Mitsuke, Y., & Iwasaki, H. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1210747 · Cited by 7
“Moreover, the combination of DIBI and fluconazole was found to inhibit the growth of fluconazole-resistant Candida albicans in an in vitro study (Savage et al., 2018).”
BackgroundLi, X., Zhang, N., Zhang, L., Liu, C., Zheng, S., & Lou, H. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s415229 · Cited by 7
“MIC in this study was defined as the lowest drug concentration of the drug capable of inhibiting cell growth by 80% in comparison with the control by visual observation.(16,17) All drug solutions were diluted twofold to achieve final concentrations ranging from 16–1024 μg/mL for LEF, 0.”
Lü, P., Moriwaki, Y., Zhang, M., Katayama, Y., Lü, Y., Okamoto, K., Terada, T., Shimizu, K., Wang, M., Kamiya, T., et al. (2019) · Metallomics · doi:10.1039/c9mt00245f · Cited by 7
Li, X., Yang, H., Duan, X., Cui, M., Xing, W., & Zheng, S. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2270160 · Cited by 7
“The MICs was determined as the lowest concentration of antifungal agents resulting in at least 80% inhibition of growth compared with the control without drugs [15,16].”
BackgroundDruseikis, M. E., Mottola, A., & Berman, J. G. (2023) · Current Clinical Microbiology Reports · doi:10.1007/s40588-023-00189-3 · Cited by 6
“Iron starvation also increased azole susceptibility in vivo in a murine vaginitis model [65].”
BackgroundElhaleem, M. B. A., Elantabli, F. M., Abbas, S. M., Taha, M., El‐Ela, F. I. A., & Elkhalik, S. A. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.114334 · Cited by 5
Holbein, B. E., Ang, M. T. C., Allan, D. S., Chen, W., & Lehmann, C. (2021) · Sustainable agriculture reviews · doi:10.1007/978-3-030-58259-3_8 · Cited by 6
Self-citationRecent advances in therapeutical applications of the versatile hydroxypyridinone chelators
Sharma, S., Baral, M., & Kanungo, B. K. (2022) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-021-01114-1 · Cited by 4
“The higher inhibition in growth by DIBI over (6) for Candida albicans [183], Acinetobacter baumannii [184], and breast cancer cells [185] were reported earlier.”
BackgroundIron chelators enhance the potency of Echinocandins against Candida aurisPreprint
Sharma, P., & Pasrija, R. (2025) · Research Square · doi:10.21203/rs.3.rs-7042978/v1 · Cited by 3
Tóth, Z., Farkas, B., Majoros, L., Jakab, Á., Borman, A. M., Varga, I., Tóth, P., & Kovács, R. (2025) · Medical Mycology · doi:10.1093/mmy/myaf116 · Cited by 3
“10 , 51 Furthermore, future studies using iron-restricted animal models are needed to better mimic various host conditions and assess the potential for therapeutic synergy.”
Genechten, W. V., Holtappels, M., Jonge, M. D., Vergauwen, R., Cornips, G., & Dijck, P. V. (2026) · mBio · doi:10.1128/mbio.00416-26 · Cited by 2
“The important role of iron regarding FLC tolerance was also shown with other iron chelators and mutants in iron transporters (12, 13).”
Prochelators modulate azole activity against Candida albicans in a metal-dependent manner
Merriman, M. A., Denning-Jannace, C. A., Hurtado, A. B., Vaccaro, F. A., Sung, Y., Tomat, E., & Franz, K. J. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00073h · Cited by 2
Iron-related immune cell function in sepsis
Thorburn, T. (2019) · DalSpace (Dalhousie University) · Cited by 3
Itoh, K., Tsutani, H., Mitsuke, Y., & Iwasaki, H. (2022) · mSphere · doi:10.1128/msphere.00373-22
“The novel iron chelator DIBI (denying iron to bacterial infections), in combination with fluconazole, showed a growth inhibition effect against fluconazole-resistant Candida albicans strains (2).”
BackgroundTARGETING IRON ACQUISITION MECHANISMS OF INVASIVE FUNGAL INFECTIONS: OLD AND NEW INSIGHTS
Iași, U., MARIAN, M., Mareș, M., & Iași, U. (2024) · Lucrări Ştiinţifice - Medicină Veterinară, Universitatea de Ştiinţe Agricole şi Medicină Veterinară "Ion Ionescu de la Brad" Iaşi · doi:10.61900/spjvs.2024.03.05
Leveraging Vulnerabilities in Copper Trafficking for Synergistic Antifungal Activity
Denning-Jannace, C. A., James, K. J., Ortiz, C. M., Sturrock, G. R., Robison, A. T. R., Vaccaro, F. A., Kuhn, S. A., Fitzgerald, M. C., & Franz, K. J. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00525
Metadata
- Authors
- Savage, K. A., Parquet, M. D. C., Allan, D. S., Davidson, R. J., Holbein, B. E., Lilly, E. A., & Fidel, P. L.
- Affiliations
- Chelation Partners Inc., Halifax, Nova Scotia, Canada
- Dalhousie University (CA)
- Louisiana State University (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-08
- Volume
- 62
- Issue
- 8
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC6105849
- OpenAlex
- W2807244885
- Cited by
- 53
- References
- 48
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 9 · 2018: 3
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-01-29)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Government of Canada
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida albicans, iron chelation, iron limitation, fluconazole, candidiasis, vaginal candidiasis, antifungal resistance, iron homeostasis, deferoxamine, deferiprone, combination antifungal therapy, mouse infection model
- MeSH terms
- Deferiprone, Animals, Antifungal Agents, Azoles, Candida, Candida albicans, Deferoxamine, Disease Models, Animal, Drug Synergism, Female, Vaginitis, Drug Resistance, Fungal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.